期刊
NEURO-ONCOLOGY
卷 15, 期 8, 页码 972-978出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/not088
关键词
adaptive; Bayesian; biomarker; clinical trials; glioblastoma
资金
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate end-points. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据